Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)

References

• Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol. 2021;893:173819. doi: 10.1016/j.ejphar.2020.173819
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Oliveira J. Advanced colorectal cancer: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(4):61–63. doi: 10.1093/annonc/mdp130
   PubMedGoogle Scholar
• Florescu-Ţenea RM, Kamal AM, Mitruţ P, et al. Colorectal Cancer: an Update on Treatment Options and Future Perspectives. Curr Health Sci J. 2019;45(2):134–141. doi: 10.12865/CHSJ.45.02.02
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345. doi: 10.1056/NEJMoa033025
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417. doi: 10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355. doi: 10.1093/annonc/mdu141
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. doi: 10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;27(24):6726–6736. doi: 10.1158/1078-0432.CCR-21-1650
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5(1):16. doi: 10.1186/s40425-017-0218-5
   PubMedGoogle Scholar
• Lazzari C, Karachaliou N, Bulotta A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol. 2018;10:1758835918762094. doi: 10.1177/1758835918762094
   Web of Science ®Google Scholar
• Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–120. doi: 10.1111/joim.12708
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773–779. doi: 10.1200/JCO.2017.76.9901
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi: 10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207–2218. doi: 10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Grothey A. Pembrolizumab in MSI-H-Dmmr Advanced Colorectal Cancer - a New Standard of Care. N Engl J Med. 2020;383(23):2283–2285. doi: 10.1056/NEJMe2031294
   PubMed Web of Science ®Google Scholar
• Barrueto L, Caminero F, Cash L, et al. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Transl Oncol. 2020;13(3):100738. doi: 10.1016/j.tranon.2019.12.010
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Arnold D, de Gramont A, et al. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol. 2018;144(6):1197–1204. doi: 10.1007/s00432-018-2632-6
   PubMed Web of Science ®Google Scholar
• Coelho MA, de Carné Trécesson S, Rana S, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083–99.e6. doi: 10.1016/j.immuni.2017.11.016
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi: 10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol. 2014;20(15):4208–4219. doi: 10.3748/wjg.v20.i15.4208
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–727. doi: 10.1038/nrc1913
   PubMed Web of Science ®Google Scholar
• Chen S, Li X, Chen R, et al. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. Oncol Lett. 2016;12(3):1868–1876. doi: 10.3892/ol.2016.4835
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hazama S, Suzuki N, et al. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci. 2017;108(3):455–460. doi: 10.1111/cas.13162
   PubMed Web of Science ®Google Scholar
• den Eynde M V, Mlecnik B, Bindea G, et al. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Cancer Cell. 2018;34(6):1012–26.e3. doi: 10.1016/j.ccell.2018.11.003
   PubMed Web of Science ®Google Scholar
• Schoppy DW, Sunwoo JB. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematol Oncol Clin North Am. 2015;29(6):1033–1043. doi: 10.1016/j.hoc.2015.07.009
   PubMed Web of Science ®Google Scholar
• Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol. 2003;3(5):361–370. doi: 10.1038/nri1083
   PubMed Web of Science ®Google Scholar
• Bhat R, Watzl C, Zimmer J. Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS One. 2007;2(3):e326. doi: 10.1371/journal.pone.0000326
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858–1872. doi: 10.1158/1078-0432.CCR-12-2426
   PubMed Web of Science ®Google Scholar
• Trivedi S, Srivastava RM, Concha-Benavente F, et al. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res. 2016;22(21):5229–5237. doi: 10.1158/1078-0432.CCR-15-2971
   PubMed Web of Science ®Google Scholar
• Lee SC, Srivastava RM, López-Albaitero A, et al. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50(2–3):248–254. doi: 10.1007/s12026-011-8231-0
   PubMed Web of Science ®Google Scholar
• Kubach J, Hubo M, Amendt C, et al. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity. Int J Cancer. 2015;136(4):821–830. doi: 10.1002/ijc.29037
   PubMed Web of Science ®Google Scholar
• Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48–60.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi: 10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Pozzi C, Cuomo A, Spadoni I, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med. 2016;22(6):624–631. doi: 10.1038/nm.4078
   PubMed Web of Science ®Google Scholar
• Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109(10):2629–2635. doi: 10.1038/bjc.2013.645
   PubMed Web of Science ®Google Scholar
• Jie HB, Schuler PJ, Lee SC, et al. CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res. 2015;75(11):2200–2210. doi: 10.1158/0008-5472.CAN-14-2788
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Ménard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075–1085. doi: 10.1084/jem.20051511
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, et al. A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-β1 Mediates Suppression in the Tumor Microenvironment. Clin Cancer Res. 2007;13(15):4345–4354. doi: 10.1158/1078-0432.CCR-07-0472
   PubMed Web of Science ®Google Scholar
• Woolston A, Khan K, Spain G, et al. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell. 2019;36(1):35–50 e9. doi: 10.1016/j.ccell.2019.05.013
   PubMed Web of Science ®Google Scholar
• Bellucci R, Martin A, Bommarito D, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824. doi: 10.1080/2162402X.2015.1008824
   PubMed Web of Science ®Google Scholar
• Concha-Benavente F, Srivastava RM, Trivedi S, et al. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016;76(5):1031–1043. doi: 10.1158/0008-5472.CAN-15-2001
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Nonomura C, Kondou R, et al. Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol. 2016;49(3):1099–1107. doi: 10.3892/ijo.2016.3586
   PubMed Web of Science ®Google Scholar
• Qiao G, Yang L, Li Z, et al. Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism. Clin Immunol. 2012;143(2):128–133. doi: 10.1016/j.clim.2012.02.006
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–1710. doi: 10.1084/jem.20130579
   PubMed Web of Science ®Google Scholar
• Tang Q, Boden EK, Henriksen KJ, et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004;34(11):2996–3005. doi: 10.1002/eji.200425143
   PubMed Web of Science ®Google Scholar
• JR G, AD L. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207–215. doi: 10.1038/icb.2010.158
   PubMed Web of Science ®Google Scholar
• Holubec L, Polivka J Jr., Safanda M, et al. The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment. Anticancer Res. 2016;36(9):4421–4426. doi: 10.21873/anticanres.10985
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015;3(10):1148–1157. doi: 10.1158/2326-6066.CIR-15-0059
   PubMed Web of Science ®Google Scholar
• Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7(23):33498–33511. doi: 10.18632/oncotarget.9256
   PubMedGoogle Scholar
• Bourhis J, Stein A, Paul de Boer J, et al. Avelumab and cetuximab as a therapeutic combination: an overview of scientific rationale and current clinical trials in cancer. Cancer Treat Rev. 2021;97:102172. doi: 10.1016/j.ctrv.2021.102172
   PubMed Web of Science ®Google Scholar
• Veluchamy JP, Spanholtz J, Tordoir M, et al. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS One. 2016;11(6):e0157830. doi: 10.1371/journal.pone.0157830
   PubMed Web of Science ®Google Scholar
• Fasano M, Della Corte CM, Di Liello R, et al. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO Open. 2020;5(5):e000753. doi: 10.1136/esmoopen-2020-000753
   PubMed Web of Science ®Google Scholar
• Elbers JBW, Al-Mamgani A, Tesseslaar MET, et al. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: results from a phase-I trial. Radiother Oncol. 2020;142:79–84. doi: 10.1016/j.radonc.2019.08.007
   PubMed Web of Science ®Google Scholar
• Lonardi S, Pietrantonio F, Prete AA, et al. 402MO Final results of the CARACAS study: randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. Ann Oncol. 2020;31:S412. doi: 10.1016/j.annonc.2020.08.513
   PubMedGoogle Scholar
• Fasano M, Della Corte CM, Viscardi G, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418. doi: 10.1177/1758835920949418
   Web of Science ®Google Scholar
• Martinelli E, Martini G, Famiglietti V, et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients with RAS Wild-type Metastatic Colorectal Cancer: the Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol. 2021;7(10):1529–1535. doi: 10.1001/jamaoncol.2021.2915
   PubMed Web of Science ®Google Scholar
• Eynde MVD, Huyghe N, Cuyper AD, et al. Interim analysis of the AVETUXIRI Trial: avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (Mcrc)—A proof of concept, open-label, nonrandomized phase IIa study. J Clin Oncol. 2021;39(3_suppl):80–. doi: 10.1200/JCO.2021.39.3_suppl.80
   Web of Science ®Google Scholar
• Stein A, Simnica D, Schultheiß C, et al. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer. 2021;9(7):e002844. doi: 10.1136/jitc-2021-002844
   PubMed Web of Science ®Google Scholar
• Sebastian S, Heinemann, Volker V. FIRE-6 Studie. Forum. 2019;34(4):371–373. doi: 10.1007/s12312-019-0657-7
   Google Scholar
• Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol. 2020;31(1):30–40. doi: 10.1016/j.annonc.2019.10.007
   PubMed Web of Science ®Google Scholar
• Lee MS, Loehrer PJ, Imanirad I, et al. Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(3_suppl):7–. doi: 10.1200/JCO.2021.39.3_suppl.7
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397(10278):1010–1022. doi: 10.1016/S0140-6736(20)32598-8
   PubMed Web of Science ®Google Scholar
• Guerrero RM, Labajos VA, Ballena SL, et al. Targeting BRAF V600E in metastatic colorectal cancer: where are we today? Ecancermedicalscience. 2022;16:1489. doi: 10.3332/ecancer.2022.1489
   PubMed Web of Science ®Google Scholar
• Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32. doi: 10.1016/j.ctrv.2019.04.003
   PubMed Web of Science ®Google Scholar
• Overman MJ, Ernstoff MS, Morse MA. Where We Stand with Immunotherapy in Colorectal Cancer: deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. Am Soc Clin Oncol Educ Book. 2018;38(38):239–247. doi: 10.1200/EDBK_200821
   PubMedGoogle Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi: 10.1038/nm1622
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi: 10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–4632. doi: 10.1002/cncr.26086
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015;33(34):4023–4031. doi: 10.1200/JCO.2015.63.2471
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103. doi: 10.1038/nature10868
   PubMed Web of Science ®Google Scholar
• Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657–667. doi: 10.1158/1078-0432.CCR-11-1446
   PubMed Web of Science ®Google Scholar
• Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. Cancer Discov. 2018;8(4):428–443. doi: 10.1158/2159-8290.CD-17-1226
   PubMed Web of Science ®Google Scholar
• Hong DS, Morris VK, El Osta B, et al. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016;6(12):1352–1365. doi: 10.1158/2159-8290.CD-16-0050
   PubMed Web of Science ®Google Scholar
• Yaeger R, Cercek A, O’Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21(6):1313–1320. doi: 10.1158/1078-0432.CCR-14-2779
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. doi: 10.1038/s12276-018-0191-1
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi: 10.1093/annonc/mdw235
   PubMed Web of Science ®Google Scholar
• Trivedi S, Concha-Benavente F, Srivastava RM, et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol. 2015;26(1):40–47. doi: 10.1093/annonc/mdu156
   PubMed Web of Science ®Google Scholar
• García-Foncillas J, Sunakawa Y, Aderka D, et al. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol. 2019;9:849. doi: 10.3389/fonc.2019.00849
   PubMed Web of Science ®Google Scholar
• Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579. doi: 10.1016/S1470-2045(14)70118-4
   PubMed Web of Science ®Google Scholar